Tag: mental health

Hallucinogen in ‘magic mushrooms’ relieves depression in largest clinical trial to date

Psilocybin, the hallucinogen found in “magic mushrooms,” helped to relieve symptoms in people with hard-to-treat depression in the largest clinical trial of its kind to date, the trial’s organizers announced Tuesday (Nov. 9).

Earlier this year, a small study suggested that psilocybin might work as well as the common antidepressant escitalopram (Lexapro) at relieving moderate to severe depression, and other past research has hinted at the drug’s promise, Live Science previously reported. But this new trial, conducted by the pharmaceutical company Compass Pathways, is the largest gold-standard trial of psilocybin to date, so its results could carry more weight than previous research, STAT reported. 

Keep reading

Lockdown has caused a mental-health crisis

What’s strange is that a mental-health lobby that has spent years redefining mental illness to include more and more people, and spent years discussing the potential social causes of this supposed ‘crisis’, is strangely hesitant to criticise lockdown. This is despite the fact that lockdown forces us into circumstances pretty much guaranteed to increase anxiety, depression and debilitating mental illnesses

A major survey by Mind, the mental-health charity, has found that two thirds of adults and three quarters of young people with existing mental-health problems have experienced worsening mental health over the course of the pandemic. In addition, more than one in five adults with no previous experience of such problems described their mental health as poor or very poor. One in four of those who tried to access support was unable to get it from the NHS.

Keep reading

Ease restrictions on medical psychedelics to aid research, experts say

Potential treatments for severe depression, addiction and other mental health disorders are being held up by excessive restrictions on psilocybin, the active ingredient in magic mushrooms, scientists and politicians have said.

Clinical trials suggest that psilocybin may be a safe and effective medicine for patients with certain psychiatric illnesses who do not respond to talking therapies, antidepressants and other drugs. But researchers say their work is being stymied by the government placing the strictest possible controls on the chemical compound.

In a report published on Monday, the Adam Smith Institute, a free market thinktank, and the Conservative drug policy reform group, urge ministers to order a review of psilocybin and remove the obstacles faced by researchers.

Under Home Office regulations, psilocybin is classified as a schedule 1 drug, along with raw opium, LSD, ecstasy and cannabis, and is not considered a medicinal compound. While clinical trials are allowed under licence, obtaining one takes more time and money than many researchers can afford, the authors say.

Robin Carhart-Harris Read more

The report calls on government to make psilocybin a schedule 2 drug, a move that would dramatically cut the cost and time taken to obtain a licence and remove the stigma surrounding research into the drug.

Keep reading